DAFNA Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

DAFNA Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Buy	+107,773	New	+$1.02M	0.19%	65
2020 Q3	–	Sell	-3,602	Closed	-$907K	–	83
2020 Q2	$907K	Sell	3,602 -21,308	-86%	-$4.31M	0.26%	60
2020 Q1	$3.92M	Buy	24,910 +15,000	+151%	+$2.54M	1.63%	18
2019 Q4	$1.62M	Hold	9,910	–	–	0.56%	44
2019 Q3	$1.45M	Hold	9,910	–	–	0.54%	48
2019 Q2	$2.06M	Sell	9,910 -257	-3%	-$55K	0.77%	36
2019 Q1	$2.12M	Buy	10,167 +5,000	+97%	+$1.1M	0.91%	33
2018 Q4	$905K	Buy	+5,167	New	+$1.03M	0.45%	51
2016 Q3	–	Sell	-13,333	Closed	-$1.2M	–	85
2016 Q2	$1.2M	Buy	+13,333	New	+$1.05M	0.95%	38
2015 Q4	–	Sell	-1,667	Closed	-$79K	–	80
2015 Q3	$79K	Buy	1,667 +447	+37%	+$29.8K	0.08%	83
2015 Q2	$113K	Buy	+1,220	New	+$123K	0.1%	72

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

DAFNA Capital Management's CRBP Position: Q2 2026 in Review

DAFNA Capital Management opened a new position in Corbus Pharmaceuticals (CRBP) in Q2 2026: 107,773 shares worth $1.01M. The stake represents 0.19% of the portfolio and ranks #65 among its holdings. This is a return to the name: DAFNA Capital Management previously reported a position in CRBP as recently as Q2 2020.

DAFNA Capital Management first reported a position in CRBP in Q2 2015 and has held it in 11 quarters since. The position peaked at $3.92M in Q1 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

DAFNA Capital Management held 107,773 shares of Corbus Pharmaceuticals worth $1.01M as of Q2 2026.
Corbus Pharmaceuticals was a new DAFNA Capital Management position in Q2 2026.
Corbus Pharmaceuticals made up 0.19% of DAFNA Capital Management's portfolio in Q2 2026, its #65 holding.
DAFNA Capital Management first reported a position in Corbus Pharmaceuticals in Q2 2015 and has held it in 11 quarters since.
DAFNA Capital Management's Corbus Pharmaceuticals position peaked at $3.92M in Q1 2020.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.